Singapore markets open in 31 minutes
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,971.27 -6.26 (-0.16%) Dow
32,394.25 -37.83 (-0.12%) Nasdaq
11,716.08 -52.76 (-0.45%) Bitcoin USD
27,297.79 +210.43 (+0.78%) CMC Crypto 200
599.08 +356.40 (+146.86%)
AZN Apr 2023 60.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:12PM EDT. Market open.
Loading interactive chart…
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
